Biofluids consist of circulating tumor cells (CTCs), cell-free nucleic acid (cfNA), or extracellular vesicles (EVs) from multiple tissues or infectious agents within the body. Rapid developments of highly sensitive and accurate analytical tools have allowed analysis of the role of these biomarkers in health, disease, and treatment response leading to targeted therapies. However, there still remains insecurity associated with biofluid-based DNA/RNA analytical methods, which must be solved before liquid biopsies can be implemented for broader routine clinical applications.
At The Liquid Biopsy Summit, experts present and consider process and technology refinements that can enable molecular liquid biopsies to become a fulcrum in the future of precision medicine.